论文部分内容阅读
[目的]总结复合性小细胞肺癌的临床特点。[方法]回顾山东省肿瘤医院胸外科1998~2010年间收治的31例复合性小细胞肺癌的临床资料,对随诊资料比较完整连续的31例患者的诊断、治疗及生存情况作一统计分析。[结果]31例复合性小细胞肺癌患者术后生存期为4.2~76.0个月,中位生存期27.0个月。Ⅰ、Ⅱ、Ⅲ期患者的中位生存期分别为33.2个月、28.0个月、19.0个月。接受术前化疗的12例复合性小细胞肺癌患者中位生存期27.4个月,未接受术前化疗的19例中位生存期25.0个月。术前化疗者有效率58.3%。肿瘤位置上周围型16例,占52.6%。[结论]复合性小细胞肺癌并不少见,具有相对独特的临床特点;化疗敏感性相对较差;手术治疗预期与分期密切相关;化疗基础上的手术切除是适合的治疗方法。
[Objective] To summarize the clinical features of small cell lung cancer. [Methods] The clinical data of 31 patients with small cell lung cancer admitted in Shandong Thoracic and Thoracic Surgery from 1998 to 2010 were retrospectively analyzed. The diagnosis, treatment and survival of 31 patients with complete follow-up data were analyzed statistically. [Results] The survival time of the 31 patients with small cell lung cancer was 4.2 to 76.0 months and the median survival time was 27.0 months. The median survival in patients with stage I, II, and III was 33.2 months, 28.0 months, and 19.0 months, respectively. The median survival of 12 patients with composite small cell lung cancer undergoing preoperative chemotherapy was 27.4 months, and 19 patients who did not receive preoperative chemotherapy had a median survival of 25.0 months. Preoperative chemotherapy were effective 58.3%. Peripheral tumor in 16 cases, accounting for 52.6%. [Conclusion] Multiple small cell lung cancer is not uncommon and has relatively unique clinical features. Chemotherapy sensitivity is relatively poor. The surgical treatment is expected to be closely related to the stage. Surgical resection based on chemotherapy is a suitable treatment.